-2%
Brigatinib is prescribed for adults with non-small cell lung cancer (NSCLC). Specifically indicated for NSCLC with a particular type of abnormal gene called anaplastic lymphoma kinase (ALK).
- The cancer should have advanced or metastasized to other parts of the body.
- Brigatinib is intended for use in adults.
- Brigatinib targets cancers with specific ALK gene abnormalities.
- The presence of the ALK gene abnormality is a key factor for prescribing Brigatinib.
- The safety and efficacy of Brigatinib in pediatric patients (children) have not been determined.
Non-small cell lung cancer (NSCLC) is a type of cancer in which malignant cells form in the tissues of the lungs. The lungs, crucial respiratory organs, consist of lobes, with the left lung having two and the right lung having three lobes. Bronchi, branching from the trachea, transport air to the lungs, and they can also be affected by lung cancer.
Key points about non-small cell lung cancer:
- There are several types of non-small cell lung cancer, each characterized by different cell types. Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are common subtypes.
- Smoking is a major risk factor for non-small cell lung cancer. Other factors, such as exposure to secondhand smoke, environmental pollutants, and a family history of lung cancer, can also contribute.
- Common signs of non-small cell lung cancer include a persistent cough and shortness of breath. Other symptoms may include chest pain, wheezing, weight loss, and recurrent respiratory infections.
- Tests that examine the lungs, such as imaging studies (CT scans, PET scans) and bronchoscopy, are employed to diagnose and stage non-small cell lung cancer.
- If lung cancer is suspected, a biopsy is typically performed to confirm the diagnosis. This involves the removal of a small tissue sample for examination under a microscope.
- Prognosis and treatment options depend on factors like the stage of cancer, overall health, and specific characteristics of the tumor. For many patients with non-small cell lung cancer, current treatments may not lead to a complete cure.
- Non-small cell lung cancer can be challenging to treat, and various approaches are employed, including surgery, chemotherapy, radiation therapy, targeted therapies, and immunotherapy.
- Ongoing research and clinical trials aim to develop new and more effective treatments for non-small cell lung cancer.